Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9577935 | 0.81 | AOC3 (0.57) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL29833611 | 0.79 | LMNA (0.47) | AOC3LMNAHIF1ACES2CES1 | |
| SCHEMBL3397481 | 0.79 | AOC3 (0.48) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL411887 | 0.78 | AOC3 (0.59) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL26025745 | 0.78 | AOC3 (0.59) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9029040 | 0.76 | AOC3 (0.47) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL6743744 | 0.76 | AOC3 (0.47) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL10626895 | 0.76 | AOC3 (0.52) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL10599811 | 0.76 | AOC3 (0.52) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL10599803 | 0.76 | AOC3 (0.52) | AOC3LMNAADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190187-A1 | FORMULATION FOR ENHANCED DELIVERY OF PHENETHYLAMINE | KNELLER BRUCE W | 2007-08-16 | — | — | US | disclosed |
| EP-0400478-A2 | Branched polycarbonates and method of preparation | GENERAL ELECTRIC COMPANY (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0378858-A2 | Process for the preparation of branched thermoplastic polycarbonates | GENERAL ELECTRIC COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190187-A1 | FORMULATION FOR ENHANCED DELIVERY OF PHENETHYLAMINE | MAOB, PNMT, MAOA | AOC3 217/4885LMNA 1997/4885ADRA2A 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.